Focal Therapy provides an option to patients between active surveillance and radical therapy, filling an important treatment gap in Prostate Cancer Management.
Focal Therapy offers many patients long-term oncological control with minimum impact on Quality of Life.
The evolution of diagnostic tools allows for new treatment options. 20 years ago, the diagnosis for Prostate Cancer was limited to Digital Rectal Exam (DRE) DRE and random biopsies. Patients were therefore left with Radical Surgery or Radiotherapy as their only options, despite the potential functional consequences. Active Surveillance was sometimes discussed but the lack of precision of the diagnostic tools did not allow physicians to safely offer this option outside of clinical trials.
Advanced imaging, targeted biopsies and genomic testing have changed the ability to localize and risk stratify the cancer. Patients are seeking an option between active surveillance and radical therapy and its potential consequences on their quality of life. Focal Therapy has the potential to fill the gap between active surveillance and radical treatments for low and intermediate-risk prostate cancer patients.
Focal One Robotic HIFU provides a safe, effective, and minimally invasive option to target and ablate the diseased portion of the prostate without damaging the surrounding tissue. Focal One is the Leading Prostate Focal Therapy platform in the hands of the urologist.
Robotic Focal HIFU Ablation is the next iteration. David Silver, MD Chief of Urology and Director of the Prostate Center at Maimonides Medical Center discusses the growing role of Focal Therapy in the management of prostate cancer.
The 2022 AUA Annual Meeting is here. Experience the Leading Prostate Focal Therapy Controlled by Urologists. Urologists around the globe will be attending the 2022 AUA Annual Meeting in New Orleans.